Peptides and antitumor activity
Tóm tắt
We developed a group of synthetic analogs of GnRH and Somatostatin to inhibit the tumor growth of different kind. The GnRH analogs decreasing the gonadotrop and steroid hormone levels act on the hormone dependent tumors and influence their growth. One of the most effective antitumor analog was patented under the name FOLLIGEN which inhibited the breast cancer caused by DMBA in rats without any side-effects. Other inhibitory analogs of GnRH with long-lasting effect were effective in the treatment of breast, ovary and prostate tumors. Another analog [α-Asp(DEA)]6,Gln8-hGnRH showed a very low endocrine but high antitumor effect in both in vitro and in vivo experiments. Its tritium labeled derivative exhibited specific binding sites on human tumor cell lines. We synthesized the analogs of GnRH-III with effective selective antitumor activity which does not alter the ovarian cycle of rats but inhibits the colony-formation of human breast cancer cell lines and has a significant antiproliferative effect. We also synthesized conjugates of potent GnRH analogs with a branched chain polylysine backbone which induce a 33–35% decrease of cell numbers of MCF-7 and MDA-MB-231 human breast cancer cell lines and 45–50% inhibition of cell proliferation. Another conjugate decreased the tumor growth of MDA-MB-231 xenografts by 80% in a treatment of 9 weeks and even tumor free animals could be found among the ones treated. Using these radiolabeled peptide hormone analogs we found that human tumor cell lines and xenografts specifically bind the GnRH conjugates. We also synthesized a series of Somatostatin analogs which inhibit tyrosine kinases and the growth of several breast, prostate and colon tumor cell lines. One of our best analogs was a heptapeptide, TT-232, which strongly inhibited the tyrosine kinase activity and the cell-proliferation in different colon tumor cells. However, it did not inhibit the growth hormone release either in vitro or in vivo from rat pituitary cells. The TT-232 was found to be effective on 60 human tumor cell lines, it significantly inhibited the tumor growth on different animal tumor models, and induced apoptosis, as a result of which some animals became tumor free. The TT-232 inhibited the tumor growth of PC3 prostate xenografts with 60% and caused a 100% survival of mice 60 days after the transplantation. It is being preclinically tested at present. We have shown that the new GnRH analogs acting without any hormonal effect and the Somatostatin analogs with strong antitumor and tyrosine kinase inhibitory activity but no hormonal effect may represent a breakthrough in the research of the antitumor peptides, having direct effect on tumor cells.
Tài liệu tham khảo
Matsuo, H., Baba, Y., Nair, R. M., Arimura, A., Schally, A. V. (1971) Structure of the porcin LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem. Biophys. Res. Commun. 43, 1334.
Burgus, R., Burcher, M., Amoss, M., Ling, N., Monahan, M. W., Rivier, J., Fellows, R., Blackwell, R., Vale, W., Guillemin, R. (1972) Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proc. Natl. Acad. Sci. USA 69, 278.
Érchegyi, J., Coy, D. H., Nekola, M. V., Coy, E. J., Schally, A. V., Mező, I., Teplán, I. (1981) Luteinizing hormone-releasing hormone analogs with increased antiovulatory activity. Biochem. Biophys. Res. Commun. 100, 915.
Karten, M. J., Rivier, J. E. (1986) Gonadotropin-releasing hormone analog design. Structure-function studies forward the development of agonist and antagonists: rationale and perspective. Endocrine Reviews 7, 44–66.
Teplán, I. (1989) Role, mechanism of action and application of gonadoliberins in reproductive processes. Acta Biologica Hungarica 40, 3–36.
Kéri, Gy., Nikolics, K., Teplán, I., Molnár, J. (1983) Desenzitization of luteinizing hormone release in cultured pituitary cells by gonadotropin-releasing hormone. Mol. Cell. Endocrinol. 30, 109–120.
Nicholson, R. J., Maynard, P. V. (1979) Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br. J. Cancer 39, 268–273.
Klijn, J. G. M., deJong, F. H. (1982) Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1, 1213–1216.
Schally, A. V., Redding, T. W., Comaru-Schally, A. M. (1983) Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate 4, 545–552.
Vincze, B., Pályi, I., Kremmer, T., Számel, I., Sugár, J., Mező, I., Seprődi, J., Teplán, I. (1990) Effect of LHRH agonist on estradiol sensitive and insensitive human breast cancer cells. J. Cancer Res. Clin. Oncol. 116, Suppl. I. 427.
Vincze, B., Pályi, I., Daubner, D., Kremmer, T., Bodrogi, I., Számel, I., Sugár, J., Seprődi, J., Mező, I., Teplán, I., Eckhart, S. (1991) Influence of luteinizing hormone releasing hormone agonist on human mammary carcinoma cell lines and their xenografts. J. Steroid Biochem. Molec. Biol. 38, 119–126.
Vincze, B., Pályi, I., Daubner, D., Kremmer, T., Bodrogi, J., Számel, I., Sugár, J., Mező, I., Seprődi, J., Teplán, I. (1990) Influence of LHRH agonist treatment on the steroid receptor synthesis in the MCF-7 cell line and in xenograft-bearing mice. In: Görög, S. (ed.) Proc. 4th Symp. Analysis of Steroids. Akadémiai Kiadó, Budapest, pp. 61–68.
Nicholson, R. I., Kéri, Gy. (1992) Antitumor activity of Folligen a novel gonadotropin analogue against DMBA-induced tumours in the rat. Tumor Biology, 13, 44–50.
Kéri, Gy., Balogh, Á., Szőke, B., Teplán, I., Csuka, O. (1991) Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal tranduction pathways in MDA-MD-231 human breast cancer cell line. Tumor Biology 12, 61–67.
Mező, I., Seprődi, J., Vincze, B., Pályi, I., Kéri, Gy., Vadász, Zs., Tóth, G., Kovács, M., Koppán, M., Horváth, E. J., Kálnay, A., Teplán, I. (1996) Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity. Biomed. Pept., Prot., Nucleic Acid 2, 33–40.
Szende, B., Takács, J., Mező, I., Szegedi, Zs., Kéri, Gy. (1994) Binding of a radiolabeled tumorselective GnRH analog to PC-3 human prostate cancer cells and the induction of apoptosis. Endocrine 2, 645–649.
Vincze, B., Pályi, I., Gaál, D., Pató, J., Móra, M., Mező, I., Teplán, I., Seprődi, J. (1996) In vivo studies of the new gonadotropin-releasing hormone antagonist-copolimer conjugates having antitumor activity. Cancer Detect, Prev. 20, 153–159.
Sower, S. A., Chiang, Y.-C., Lovas, S., Conlon, J. M. (1993) Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. Endocrinology 132, 1125–1131.
Lovas, S., Conlon, J. M., Vincze, B., Pályi, I., Gaál, D., Seprődi, J., Kálnay, A., Mező, I., Teplán, I., Tóth, G., Kovács, M. (1997) Anti-tumor effect of GnRH-III. US. Pat. No.: 5,593,965
Lovas, S., Pályi, I., Vincze, B., Mező, I., Teplán, I., Tóth, G., Kovács, M., Murphy, R. F. (1998) Antitumor activity of lamprey-GnRH-III. Peptides Res. J. Peptide Res. 52, 389–398.
Mező, I., Lovas, S., Pályi, I., Vincze, B., Kálnay, A., Turi, G., Vadász, Zs., Seprődi, J., Idei, M., Tóth, G., Gulyás, É., Ötvös, F., Mák, M., Horváth, E. J., Teplán, I., Murphy, R. F. (1998) Synthesis of gonadotropin-releasing hormone III. analogs, structure-antitumor activity relationships. J. Med. Chem. 40, 3353–3358.
Vincze, B., Pályi, I., Daubner, D., Kálnay, A., Mező, I., Hudecz, F., Szekerke, M., Teplán, I., Mező, I. (1994) Antitumor effect of a gonadotropin-releasing hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts. J. Cancer Res. Clin. Oncol. 120, 578–584.
Mező, G., Mező, I., Pimm, V. M., Kajtár, M., Seprődi, J., Teplán, I., Kovács, M., Vincze, B., Pályi, I., Idei, M., Szekerke, M., Hudecz, F. (1996) Synthesis conformation, biodistribution and hormonrelated in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate. Bioconjugate Chem. 7, 642–650.
Pályi, I., Vincze, B., Kálnay, A., Turi, G., Mező, I., Teplán, I., Seprődi, J., Pató, J., Móra, M. (1996) Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lines. Cancer Det. Prev. 20, 146–152.
Mező, I., Seprődi, J., Vadász, Zs., Teplán, I., Vincze, B., Pályi, I., Kálnay, A., Turi, G., Móra, M., Pató, J., Tóth, G., Lovas, S., Murphy, R. F. (1996) Antitumor activity of GnRH analogs and their conjugates with poly(N-vinylpyrrolidone-co-maleic acid). In: Kaumaya, P. T. P., Hodges, R. S. (eds), Peptides: Chemistry, Structure and Biology. Mayflower Scientific Ltd. Kingswinford, pp. 239–240.
Mező, I., Teplán, I., Seprődi, J., Morgat, J. L., Fromageot, P., Tóth, G., Sirokmán, F. (1978) Synthesis of (Tyr-3H)4-Angiotensin II. and (Phe-3H)8-Angiotensin II. via halogen-derivatives of Angiotensin II. J. Lab. Comp. Radiopharm. 14, 557
Vincze, B., Pató, J., Mező, I., Tóth, G., Pályi, I., Gaál, D., Kálnay, A., Stefik, I., Lovas, S., Teplán, I., Murphy, R. F. (1997) GnRH analogue conjugates with selective antitumor activity: pharmacological studies. Proc. Am. Assoc. Cancer Res. 38, 433.
Mező, I., Vincze, B., Pató, J., Pályi, I., Tóth, G., Gulyás, É., Kálnay, A., Teplán, I., Lovas, S., Murphy, R. F. (1998) Studies on antitumor activity of GnRH analog conjugates. In: Bajusz, S., Hudecz, F. (ed.) Peptides, Akadémiai Kiadó, Budapest, p. 436.
Kéri, Gy., Mező, I., Vadász, Zs., Horváth, A., Idei, M., Vántus, T., Balogh, Á., Bökönyi, Gy., Bajor, T., Teplán, I., Tamás, J., Mák, M., Horváth, J., Csuka, O. (1993) Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Peptide Research 6, 281–288.
Kéri, Gy., Mező, I., Horváth, A., Vadász, Zs., Balogh, Á., Idei, M., Vántus, T., Teplán, I., Mák, M., Horváth, J., Pál, K., Csuka, O. (1993) Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochem. Biophys. Res. Commun. 191, 681–687.
Kéri, Gy., Érchegyi, J., Horváth, A., Mező, I., Idei, M., Vántus, T., Balogh, Á., Vadász, Zs., Bökönyi, Gy., Seprődi, J., Teplán, I., Csuka, O., Tejeda, M., Gaál, D., Szegedi, Zs., Szende, B., Roze, C., Kalthoff, H., Ullrich, A. (1996) A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc. Natl. Acad. Sci. USA 93, 12513–12518.
Vántus, T., Csermely, P., Teplán, I., Kéri, Gy. (1995) The tumor-selective somatostatin analog, TT-232 induces a biphasic activation of phospotyrosine phosphatase activity in human colon tumor cell line, SW620. Tumor Biology 16, 261–267.
Kéri, Gy., Érchegyi, J., Horváth, A., Idei, M, Teplán, I., Csuka, O., Tajeda, M., Gaál, D., Őrfi, L., Szegedi Zs., Szende, B. (1998) Induction of apoptosis and non-apoptotic programmed cell death by antitumor peptides and peptidomimetics. In: Ramage, R., Epton, R. (eds) Peptides p. 83.
Sarkadi, B., Seprődi, J., Teplán, I., Mező, I., Vadász, Zs., Magócsi, M., Vincze, B., Pályi, I., Csuka, O., Vegyületek drogrezisztencia megszüntetésére, Magyar szabadalom: 215132 (1998), PCT bejelentés: IB 9400144.
Seprődi, J., Mező, I., Vadász, Zs., Szabó, K., Sarkadi, B., Teplán, I. (1998) Peptide derivatives against multidrug resistance. In: Ramage, R., Epton, R. (eds) Peptides p. 801.